Inspire's $24.1 Million Project Horizon Charge Is Mostly Factory Equipment Written Down To Zero
Severance was only $3.1 million of the charge, and the Project Horizon risk warning from the prior quarter is gone.
Inspire Medical Systems, which makes an implanted sleep apnea device, booked a $24.1 million restructuring charge in the third quarter. Of that, $21.1 million is production equipment written down to zero because the company will neither use nor sell it, according to its 10-Q filed Monday.
Equipment, not severance
The charge sits inside a third-quarter operating loss of $28.7 million, against operating income of $9.6 million a year earlier. Revenue fell 7.9% to $206.7 million.
The $21.1 million impairment is non-cash. The company is ending some manufacturing, and the filing says the equipment had "no alternative use or expected disposal proceeds." Severance and termination benefits were just $3.1 million.
The prior quarter's filing guided to $4 million to $5 million of severance and $16 million to $20 million of non-cash expense, with total charges of $20 million to $25 million. The new filing says about $4 million, about $21 million and about $25 million. The accrued severance balance is $1.5 million, mostly payable in the fourth quarter and early 2027.
A warning that disappeared
The risk factor Inspire added last quarter for Project Horizon, which cautioned about attrition beyond the intended number of employees, no longer appears. The 10-Q says there were no material changes to risk factors.
Project Horizon, announced August 3, is meant to free about $30 million a year of investment capacity for revenue growth. The company says most of the restructuring actions were completed in the third quarter and all should be substantially complete by the end of 2026.
The quarter also carries a $7.0 million legal settlement expense. On October 5, Inspire agreed to a binding term sheet resolving a class action over website pixel tracking, while denying the allegations.
Reimbursement drag continues
Inspire sells its system to hospitals and ambulatory surgery centers. Management says coding and reimbursement confusion around the Inspire V device hurt revenue in the first nine months of 2026 and will keep doing so through year-end. Delays tied to Medicare's prior-authorization pilot, known as WISeR, also weighed, though less so in the remainder of the year.
The company expects final 2027 Medicare rates in November, and new billing codes take effect January 1, 2028. A hearing on the motion to dismiss the securities class action over the Inspire V launch is set for February 2027.
Inspire bought back no shares in the first nine months of 2026, versus $50 million at $90.49 a share in the prior-year third quarter. It has $100.0 million of authorization left. Its market value was $2.0 billion after Monday's session.
The company has narrowed its 2026 revenue outlook to $850 million to $860 million, from $835 million to $875 million.
Sources
- 10-Q Filing — Inspire Medical Systems (INSP) — SEC EDGAR
- 10-Q Filing — Inspire Medical Systems (INSP), Q2 FY2026 filed 2026-08-03 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, insp2026-q3pressreleaseex9.htm) — Inspire Medical Systems, filed 2026-11-02 — SEC EDGAR
- Inspire Medical Systems (NYSE:INSP) beats Q3 2026 sales expectations — Yahoo Finance
- Inspire Medical Systems Non-GAAP EPS of $0.14 beats by $0.05, revenue of $206.7M beats by $2.39M (INSP:NYSE) | Seeking Alpha — seekingalpha.com
- Inspire Medical Systems, Inc. Announces Third Quarter 2026 — globenewswire.com
